Pfizer has issued a communication about a potential for injecting an excess volume of pegaptanib sodium (Macugen®) intravitreally. This risk has been identified in a clinical trial and in clinical practice. Two cases have been reported in which a volume of Macugen greater than the recommended volume (90 ?L) was injected into a patient's eye with a subsequent elevation of intraocular pressure (lOP). In both cases, the lOP became elevated to a level which required anterior chamber paracentesis.
The Company advises that to ensure the (Read more...)